AdvanDx, Inc. Launches the First LNA-Based In Vitro Diagnostic Test for Detection of Antibiotic Resistant ''Superbugs''
WOBURN, Mass.--(BUSINESS WIRE)--AdvanDx, Inc. today announced the launch of vanA/B EVIGENE in Europe, the first LNA-based in vitro diagnostic test for detecting the antibiotic resistant “Superbugs” Vancomycin-Resistant Enterococci (VRE) and Vancomycin-Resistant Staphylococcus aureus (VRSA) in positive blood cultures and clinical isolates.